Anti-phage colony infection strain, anti-phage element and its application
By integrating and optimizing the anti-phage element PD-AR2 in E. coli, the strain E. coli PRE12 with excellent invasion performance in phage population was screened, which solved the problem of poor resistance to bursts of various phage populations by existing anti-phages, achieving the goal of achieving Effective defense and industrial application in complex environments.
Patent Information
- Application Number
- CN202311623391.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-11-30
AI Technical Summary
The existing anti-phage E. coli has poor resistance to outbreaks of multiple phage groups, and it is difficult to effectively defend against the joint infection of multiple phages in complex environments.
Through CRISPR/Cas9 technology, the anti-phage element PD-AR2 is integrated in E. coli, and the strain E. coli PRE12 with excellent anti-phage population infection performance is screened and optimized. This strain and its metabolic solution are used to resist phage infection and prevent phage infection. Applied in.
E. coli PRE12 significantly improves its resistance to multiple phage populations, can effectively defend against the common outbreak of multiple phages in complex environments, and does not affect the growth of the strain and the expression of recombinant proteins. It is suitable for industrial production.
Smart Images

Figure GDA0004901814960000051 
Figure HDA0004579905940000011 
Figure HDA0004579905940000012
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of genetic engineering and microbial engineering, and particularly relates to a strain resistant to bacteriophage colony infection, an anti-bacteriophage element and applications thereof. Background Art
[0002] Bacteriophages are a type of virus that infects bacteria, actinomycetes and other microorganisms. They are numerous, small in size, reproduce quickly, and have high genome plasticity. They are the most common and widely distributed group of viruses. Bacteriophage contamination is diverse and stubborn. Once bacteriophage contamination occurs in biological fermentation enterprises, if it is not handled in time, it will spread rapidly and even repeatedly, causing immeasurable losses.
[0003] Faced with phages that are much more abundant in nature than their own, bacteria have evolved to adapt to this long-term survival pressure through co-evolution, and have developed a variety of defense mechanisms against phage infection, which work at different stages of the phage infection process, such as the CRISPR system and the restriction modification (RM) system (Tock Mark R, Dryden David TF, The biology of restriction and anti-restriction. [J]. Curr Opin Microbiol, 2005, 8: 466-72). At present, the industry uses domestication to select phage-resistant strains, which are widely used because of their simple operation and significant effects. However, currently, various laboratories and production companies will consciously divide time and space when studying phage-resistant Escherichia coli. They either study the infection of one phage to obtain Escherichia coli that is resistant to a single phage, or study the separate infections of different phages to obtain Escherichia coli that is resistant to a broad-spectrum phage. However, there are many types of phages in the environment. The phages that infect in the same period and space are often not of a single type, but an outbreak of multiple phages. We can call this pollution phenomenon a phage population outbreak. These single-lineage and broad-spectrum phage-resistant Escherichia coli have little effect in the face of phage population outbreaks that are often encountered in actual fermentation production scenarios. Summary of the invention
[0004] Purpose of the invention: In view of the problems existing in the above-mentioned prior art, the present application provides a strain resistant to phage colony infection, an anti-phage element and its application.
[0005] Technical solution: This application discloses a strain of Escherichia coli PRE12, which was deposited in the China Center for Type Culture Collection on May 4, 2023, with the deposit address being Wuhan University, Wuhan, China, and the deposit number being CCTCC NO: M2023669.
[0006] The E. coli PRE12 is obtained by integrating and expressing anti-phage elements and performing cross-mutation treatment on E. coli BL21 (DE3), which is susceptible to phage contamination. The genetic engineering modification uses CRISPR / Cas9 technology to insert the anti-phage element into the E. coli IS sequence, which is a multi-copy sequence on the E. coli genome, and screen the optimal expression level single clone, which has the best performance in resisting phage colony infection.
[0007] Among them, the genetic engineering modification step is: from the environmental microbial genome, after screening and optimization, obtain the anti-phage element PD-AR, after truncation screening, preferably PD-AR2, and further preferably P EM7 The expression of PD-AR2 element was initiated, and the anti-phage element PD-AR2 was integrated and expressed at the IS sequence of Escherichia coli. The anti-phage performance of positive clones containing different copies was detected, and the best single clone was further selected for application in resisting phage group infection.
[0008] The DNA library is prepared in the following specific methods: environmental microorganisms are picked and cultured from the laboratory and fermentation plant environment of the contaminated phage, and the cultured microbial genome is extracted using a DNA extraction kit (Novozyme, catalog number: DC103-01). The restriction endonucleases BamHI (Takara, catalog number: 1010S) and NdeI (Takara, catalog number: 1161A) are used to double-digest genomic DNA to obtain DNA fragments of different sizes, and double-digest plasmid pET-28a (+) (Ubao Biology, catalog number VT1207) to obtain linearized pET-28a (+) vectors, and gel recovery of 3000-8000bp genomic DNA fragments and linearized vectors. Use T4 ligase (Novozyme, catalog number: N103-01) to connect, transform DH5α competent state (Novozyme, C502-02), and extract plasmids to obtain DNA libraries.
[0009] The DNA library screening and optimization method is as follows: the DNA library plasmid is transformed into Escherichia coli BL21 (DE3), inoculated with LB medium (added with 0.5 mM IPTG), respectively at 16°C and 37°C, and mixed with phages of different dilution gradients as screening pressure (the initial phage titer is about 10 8 pfu / mL) and co-cultured until OD 600 About 0.4, coated on LB solid plate, after the colony grew, streaked and picked single clones for plaque detection, screened the strain with the best anti-phage colony infection ability, extracted plasmids for sequencing, and obtained the anti-phage sequence PD-AR, whose deoxyribonucleotide sequence is shown in SEQ ID NO.2. According to the open reading frame and amino acid comparison information, different sequences were obtained by truncating and inserted into the P of the self-constructed vector pCYap AmpRor P EM7 Downstream of the promoter, BL21 (DE3) was transformed for plaque detection, and the preferred sequence PD-AR2 was used as the anti-phage element, and its deoxyribonucleotide sequence was shown in SEQ ID NO.1.
[0010] The mutagenesis screening method is as follows: after treating Escherichia coli with 0.1-0.6g / L nitrosoguanidine (NTG) as a mutagen for 20-60min, immediately wash it three times with 4°C pre-cooled PBS to terminate the reaction. Add 1mL of fresh LB culture medium, 37°C, 200rpm to recover for 2-3h, centrifuge to remove the supernatant and add an equal volume of 0.9% sterile saline to resuspend. After irradiating with ultraviolet light (30W ultraviolet lamp) for 10-300s, cover the dish lid, turn off the ultraviolet light, take 4mL of fresh LB culture medium in the culture dish, shake to mix, 200rpm, keep at 37°C in the dark for 12-16h. Take 1mL of culture solution and add 5mL of fresh LB culture medium, 37°C, 200rpm to recover for 4-6h, take 500μL of bacterial solution and 50μL of phage mixture with different dilution gradients (the initial phage titer is about 10 8 pfu / mL) and inoculate 50mL LB medium until OD 600 When it grows to about 0.4, take an appropriate amount of bacterial liquid to spread on LB solid plates and culture at 37°C for 18-36 hours. After the colonies grow, streak to obtain potential positive multi-resistant phage strain monoclonal clones. Pick out the positive monoclonal clones with good growth and repeat the mutagenesis screening steps of "NTG treatment - recovery - UV treatment - recovery - phage co-culture" until a positive monoclonal clone with good anti-phage performance and good growth is obtained.
[0011] The plaque detection method is as follows: different genetically engineered or mutagenized E. coli monoclones and E. coli BL21 (DE3) are selected for recovery and cultured overnight, and about 1×10 9 Add 5 mL of semi-solid LB medium to each cell and mix well, then spread it on the top of the LB solid plate. Place it at room temperature for 5-10 minutes. After solidification, divide the plate into 2-3 equal areas and drop 5 μL of phage mixture with different dilution gradients (the initial phage titer is about 10 8 pfu / mL), mark it, culture it for 12-24h, and observe the plaques.
[0012] The present application also discloses the use of the Escherichia coli PRE12 or its bacterial liquid or its metabolic liquid or its culture liquid in resisting phage infection and / or preventing and treating phage infection.
[0013] Wherein, the phage is selected from one or more of dsDNA phage and ssDNA phage.
[0014] The dsDNA phage is selected from T1, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, ADB-2, P7, T7, S-CRM01, HK630, VCO139, vB_EcoM-FV3, phiAC-1, vB_XveM_DIBBI, P-SSM7, BPS13, P-SSM3, mEp237, vB_CsaP_GAP52, EcP1, LIT1, Syn33 , vB_CsaM_GAP32, 9NA, phi92, HK629, RE-2010, RAP44, vB_BanS-Tsamsa, TL-2011b, SfII, Stx2-convertingphag e1717, Lu11, YYZ-2008, HK106, S-SM2, RcapNL, vB_CsaM_GAP161, GBSV1, JSE, RB49, GEC-3S, KP36, phiEa100, FSL SP-101, Era103, Aaphi23, S1249, HX01, pIS4-A, pYD38-A, OBP, mEp460, phiEaH2, vB_KleM-RaK2, PX29, SPN3US, CcrColossus, JLK-2012, cdtI, SfI, VT2phi_272, Acj9, 201phi2-1, CR9, PhiPA3, Clostridiumphage c-st, Stx2a_WGPS2, phiR1-37, PA7, Myrna, mEp235, PaMx42, Thibault, phiMAM1, HK140, VH7D, ECML-117, etc.; the ssDNA phage is selected from Ike, ID18, ID2 Moscow / ID / 2001, G4 (coliphage), Coliphage ID52, St-1, ColiphageWA45, Coliphage NC35, Coliphage NC29, WA13, etc.
[0015] The present application also discloses the use of the Escherichia coli PRE12 or its bacterial liquid or its metabolic liquid or its culture liquid in expressing recombinant proteins.
[0016] The recombinant protein expression method comprises the following steps: inserting the coding gene of the recombinant protein into an expression plasmid, transforming Escherichia coli E.coli PRE12 to obtain a recombinant protein expression strain; inducing expression of the recombinant protein expression strain to obtain the recombinant protein.
[0017] The present application also discloses an anti-phage element PD-AR2, whose nucleotide sequence is shown in SEQ ID NO.1.
[0018] The anti-phage element is obtained by screening a DNA library, specifically from the genome of environmental microorganisms, through screening and optimization, to obtain the anti-phage element PD-AR, and through truncation screening, preferably PD-AR2 is obtained.
[0019] The present application also discloses the use of the anti-phage element PD-AR2 in improving the resistance of chassis cells to phage infection.
[0020] Wherein, the chassis cells are Escherichia coli, preferably Escherichia coli BL21 (DE3).
[0021] Wherein, the bacteriophage is selected from one or more of dsDNA phage and ssDNA phage.
[0022] The dsDNA phage is selected from T1, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, ADB-2, P7, T7, S-CRM01, HK630, VCO139, vB_EcoM-FV3, phiAC-1, vB_XveM_DIBBI, P-SSM7, BPS13, P-SSM3, mEp237, vB_CsaP_GAP52, EcP1, LIT1, Syn33 , vB_CsaM_GAP32, 9NA, phi92, HK629, RE-2010, RAP44, vB_BanS-Tsamsa, TL-2011b, SfII, Stx2-convertingphag e1717, Lu11, YYZ-2008, HK106, S-SM2, RcapNL, vB_CsaM_GAP161, GBSV1, JSE, RB49, GEC-3S, KP36, phiEa100, FSL SP-101, Era103, Aaphi23, S1249, HX01, pIS4-A, pYD38-A, OBP, mEp460, phiEaH2, vB_KleM-RaK2, PX29, SPN3US, CcrColossus, JLK-2012, cdtI, SfI, VT2phi_272, Acj9, 201phi2-1, CR9, PhiPA3, Clostridiumphage c-st, Stx2a_WGPS2, phiR1-37, PA7, Myrna, mEp235, PaMx42, Thibault, phiMAM1, HK140, VH7D, ECML-117, etc.; the ssDNA phage is selected from Ike, ID18, ID2 Moscow / ID / 2001, G4 (coliphage), Coliphage ID52, St-1, ColiphageWA45, Coliphage NC35, Coliphage NC29, WA13, etc.
[0023] The present application also discloses an expression vector comprising the gene shown in SEQ ID NO.1.
[0024] Beneficial effects: The present application obtains the anti-phage element PD-AR2 by preparing a DNA library, screening and optimizing, and the anti-phage element can be used to improve the resistance of chassis cells to phage infection. The present application uses Escherichia coli E. coli BL21 (DE3) to successfully transform and screen to obtain a multi-phage-resistant chassis cell E. coli PRE12, which has good tolerance to phage group infection and has a broad spectrum. It can adapt to the complex environment of single phage outbreaks and phage group outbreaks at the same time, and will not affect the growth of E. coli itself and the expression of recombinant proteins, and is suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 It is the nucleic acid electrophoresis diagram of the environmental microorganism genome double digested by restriction endonucleases BamHI and NdeI;
[0026] Figure 2 Schematic diagram of pET-28a(+)-PD plasmid, where PD represents genomic DNA fragments of different sizes;
[0027] Figure 3 Schematic diagram of pCYap-PD-ARx plasmid, where PD-ARx represents different truncated fragments of PD-AR;
[0028] Figure 4 The plaque detection images of strains expressing different truncations of PD-AR anti-phage fragments;
[0029] Figure 5 Integration of expression cassette HA1-P for anti-phage element EM7 - Schematic diagram of PD-AR2-HA2;
[0030] Figure 6 Schematic diagram of plasmid pCas9-V2, which contains the N20 sequence from the genomic IS sequence target, i.e., the spacer sequence;
[0031] Figure 7 This is a plaque detection diagram, which is a detection diagram of the anti-phage performance of some intermediate strains in the process of Escherichia coli anti-phage transformation and screening;
[0032] Figure 8 This is a plaque detection diagram, which is the anti-phage performance test diagram of E. coli PRE12 and E. coli BL21 (DE3) against 6 groups of contaminated batches of phage samples. The phage samples were diluted to 10 0 , 10 -2 , 10 -4 Three gradients;
[0033] Fig. 9This is a plaque detection diagram, which is the anti-phage performance test diagram of E. coli E. coli PRE12, E. coli BL21 (DE3), and ER2566 against two groups of contaminated batches of phage samples. The phage samples were diluted to 10 0 , 10 -2 , 10 -4 Three gradients;
[0034] Fig.10 It is the growth curve of E. coli PRE12 (square) and E. coli BL21 (DE3) (circle) in LB medium and TB medium;
[0035] Fig.11 This is the SDS-PAGE image of E. coli PRE12, E. coli BL21 (DE3) and ER2566 expressing EGFP protein. S indicates soluble, P indicates inclusion body, and the arrow points to the target protein. DETAILED DESCRIPTION
[0036] The following examples further illustrate and help understand the technical solution of the present application, but should not be construed as limiting the scope of protection of the present application.
[0037] The E. coli BL21 (DE3) in the following examples is a product of Novagen, BL21 (DE3) Competent Cell, with a catalog number of 69450-3CN.
[0038] The culture medium involved in the following examples is as follows:
[0039] LB medium: 10g / L peptone, 5g / L yeast extract, 10g / L sodium chloride. Adding 0.6% agar powder can be configured as LB semi-solid medium, and adding 1.2% agar powder can be configured as LB solid medium.
[0040] TB liquid culture: 20 g / L peptone, 24 g / L yeast powder, 72 mM K2HPO4, 17 mM KH2PO4, 0.4% glycerol.
[0041] Phage mixture (as screening pressure, it comes from the mixture of contaminated phages in the actual production process, and is identified by NGS sequencing. The phage types included are: I: dsDNA phages, such as vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, ADB-2, P7, T7, S-CRM01, HK630, VCO139, vB_EcoM-FV3, phiAC-1, vB_XveM_DIBBI, P-SSM7, BPS13, P-SSM3, mEp237, vB_CsaP_GAP52, EcP1, LIT1, Syn33, vB_CsaM_GAP32, 9NA, phi92, HK629, RE-2010, RAP44, vB_BanS-Tsamsa, TL-2011b, SfII, Stx2-convertingphage 1717, Lu11, YYZ-2008, HK106, S-SM2, RcapNL, vB_CsaM_GAP161, etc.; II: ssDNA phages, such as Ike, ID18, ID2 Moscow / ID / 2001, G4 (coliphage), Coliphage ID52, St-1, Coliphage WA45, etc. The initial phage mixture titer is about 10 8 pfu / mL).
[0042] Phage-like (8 groups of phage-like, the initial phage titer is about 10 8 pfu / mL, numbered P01-P08, derived from actual production workshop and laboratory contaminated environment, identified by NGS sequencing:
[0043] The phage types of P01 samples covered I: dsDNA phages, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, ADB-2, P7, T7, S-CRM01, HK630, VCO139, vB_EcoM-FV3, phiAC-1, vB_XveM_DIBBI, P-SSM7, BPS13, P-SSM3, mEp237, vB_CsaP_GAP52, EcP1, LIT1, Syn33, vB_CsaM_GAP32, 9NA, phi92, HK629, RE-2010, RAP44, vB_BanS-Tsamsa, GBSV1, JSE, RB49, GEC-3S, KP36, phiEa100, FSL SP-101, Era103, Aaphi23, S1249, HX01, pIS4-A, pYD38-A, SfII, etc.; II: ssDNA phage, Ike.
[0044] The phage types of P02 samples cover I: dsDNA phages, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, T7, P7, ADB-2, HK630, HK629, S-CRM01, RE-2010, vB_XveM_DIBBI, mEp237, P-SSM3, vB_EcoM-FV3, LIT1, VCO139, P-SSM7, Syn33, phi92, phiAC-1, BPS13, vB_CsaM_GAP32, vB_CsaP_GAP52, EcP1, RAP44, 9NA, vB_BanS-Tsamsa, SfII, JSE, RB49, etc.; II: ssDNA phages, Ike.
[0045] The phage types of P03 samples cover I: dsDNA phages, HK630, RE-2010, HK629, TL-2011b, SfII, Stx2-converting phage 1717, T7, Lu11, YYZ-2008, OBP, mEp460, vB_CsaM_GAP32, phiEaH2, HK106, P7, PX29, SPN3US, CcrColossus, S-SM2, JLK-2012, cdtI, SfI, vB_CsaM_GAP161, VT2phi_272, Acj9, 201phi2-1, CR9, PhiPA3, Clostridiumphage c-st, Stx2a_WGPS2, phiR1-37, PA7, Myrna, etc.
[0046] The phage types of P04 samples include: dsDNA phage, HK630, RE-2010, HK629, TL-2011b, T7, SfII, HK106, Stx2-converting phage 1717, Lu11, YYZ-2008, mEp460, vB_CsaM_GAP32, OBP, phiEaH2, SfI, P7, JLK-2012, CcrColossus, Acj9, SPN3US, PX29, vB_CsaM_GAP161, cdtI, 201phi2-1, PhiPA3, S-SM2, phiR1-37, VT2phi_272, c-st, mEp235, CR9, Myrna, PaMx42, Stx2a_WGPS2, PA7, phi92, Thibault, phiMAM1, HK140, etc.
[0047] The phage types of P05 samples covered I: dsDNA phages, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, ADB-2, RE-2010, P7, S-CRM01, HK630, BPS13, T7, vB_EcoM-FV3, vB_XveM_DIBBI, vB_CsaM_GAP32, VCO139, P-SSM7, mEp237, phiAC-1, P-SSM3, EcP1, vB_CsaP_GAP52, Syn33, phi92, 9NA, LIT1, RAP44, HK629, vB_BanS-Tsamsa, SfII, JSE, GBSV1, RB49, KP36, GEC-3S, FSL SP-101, Era103, S1249, phiEa100, Aaphi23, etc.; II: ssDNA phage, Ike.
[0048] The phage types of P06 samples include I: dsDNA phages, RE-2010, HK630, S-SM2, HK629, TL-2011b, RcapNL, vB_CsaM_GAP161, SfII, VH7D, phiEaH2, Lu11, vB_CsaM_GAP32, Stx2-convertingphage 1717, CcrColossus, vB_EcoS_ACG-M12, YYZ-2008, PX29, ECML-117, SPN3US, 201phi2-1, OBP, mEp460, P7, etc.; II: ssDNA phages, ID18, ID2 Moscow / ID / 2001, G4(coliphage), Coliphage ID52, St-1, Coliphage WA45, Coliphage NC35, Coliphage NC29, WA13.
[0049] The phage types of P07 samples cover I: dsDNA phage, vB_EcoS_ACG-M12, phiEB49, phiJLA23, vB_EcoS_Rogue1, P7, PVL, HK629, HK630, JS01, phiPVL-CN125, T7, StauST398-4, Stx2a_F451, etc.
[0050] The phage types of P08 samples cover I: dsDNA phages, vB_EcoS_ACG-M12, phiJLA23, StausT398-4, phiEB49, P954, PVL, SP5, phiPV83, HK633, P7, vB_EcoS_Rogue1, JS01, phi7247PVL, phi7401PVL, phiPVL-CN125, SMSAP5, tp310-1, tp310-2, tp310-3, etc.
[0051] Embodiment 1
[0052] Screening of anti-phage elements, the specific steps are as follows:
[0053] (1) From the environment of the phage outbreak, the surviving environmental microorganisms were selected for mixed culture, and the total genome of the cultivated environmental microorganisms was extracted using a genome extraction kit (Novozymes, Catalog No. DC103-01). The restriction endonucleases BamHI (Takara, Catalog No.: 1010S) and NdeI (Takara, Catalog No.: 1161A) were used to double-digest the environmental microorganism genome to obtain DNA fragments PD of different sizes, such as Figure 1As shown. Using the gel recovery kit (Novozyme, catalog number: DC301-01), DNA gel was used to recover DNA fragments of 3000-8000 bp.
[0054] (2) pET-28a(+) (Ubao Biotechnology, Catalog No. VT1207) was double-digested with restriction endonucleases BamHI and NdeI to obtain a linearized vector. The recovered fragments were ligated to the linearized vector using T4 ligase (Novozyme, Catalog No. N103-01) to obtain plasmid pET-28a(+)-PD. Figure 2 As shown, DH5α competent cells (Novozyme, C502-02) were transformed, and the plasmid was extracted to obtain a DNA library.
[0055] (3) The prepared DNA library plasmid was transformed into E. coli BL21 (DE3), coated with LB solid plates (containing 50 μg / mL kan), and placed in a 37°C constant temperature incubator for 12-24 h.
[0056] (4) Use 3 mL of fresh LB medium to suspend the transformants on the plate to obtain a mixed bacterial solution of transformants, transfer to LB medium (50 mL / 250 mL conical flask, add 0.5 mM IPTG), and inoculate 50 μL of phage mixture with different dilution gradients (the initial phage titer is about 10 8 pfu / mL), and cultured at 37°C and 16°C, 200 rpm until OD 600 When the pH is about 0.4, spread on LB solid plate (0.5 mM IPTG, 50 μg / mL kan) and place in a 37°C constant temperature incubator for 12-24 h.
[0057] (5) After the colonies grow, streak and pick different positive single clones and the control strain E. coli BL21 (DE3) (carrying pET-28 (+) plasmid) to inoculate 3 mL LB liquid medium, culture at 37°C, 200 rpm for 6-8 h, and then transfer 1% of the inoculum to LB medium (50 mL / 250 mL conical flask, add 0.5 mM IPTG), and culture at 37°C and 16°C, 200 rpm for 8-12 h. Take about 1×10 9 Add 5 mL of semi-solid LB medium containing 50 μg / mL kan and 0.5 mM IPTG to each cell, mix well, and spread on the upper layer of the LB solid plate (containing 50 μg / mL kan). Leave at room temperature for 5-10 minutes. After solidification, divide the plate into two equal areas and drop 5 μL of a dilution gradient of 10 0 , 10 -2 of phage mixture (the initial phage titer was about 10 8 pfu / mL), mark it, culture it for 12-24h, and observe the plaque formation.
[0058] (6) The corresponding strain with the best ability to resist infection by the phage group was selected, inoculated into LB medium, cultured overnight at 37°C and 200 rpm, and then the plasmid was extracted and sequenced to obtain the anti-phage related fragment PD-AR, whose deoxyribonucleotide sequence is shown in SEQ ID NO.2.
[0059] (7) The PD-AR sequence was compared on NCBI and the sequence was identified as being derived from Escherichia coli (serial number: CP043541.1), with 100% similarity. Based on the open reading frame information and amino acid comparison analysis, the PD-AR sequence was truncated to obtain PD-AR1 (1-4085 bp), PD-AR2 (1682-4085 bp), and PD-AR3 (2119-4049 bp) fragments.
[0060] (8) Amplify or splice the KanR resistance gene, p15Aori replicon sequence, and P AmpR or P EM7 The promoter sequence and rrnB T1 / T2 terminator sequence were tandemly spliced to obtain the vector pCYap-P AmpR or pCYap-P EM7 Using the vector as a template, primer pairs Primer1 / Primer2 or Primer1 / Primer2-2 were used to amplify the vector carrying P AmpR or P EM7 Linearized vector containing promoter.
[0061] (9) Using the PD-AR fragment as a template, primer pairs Primer3 / Primer4, Primer5 / Primer6, and Primer7 / Primer8 were used to amplify PD-AR1, PD-AR2, and PD-AR3 fragments, respectively. The primers are shown in Table 1.
[0062] Table 1
[0063]
[0064] Using a one-step cloning kit (Novozyme, catalog number: C115-01), the PD-ARx series fragments were inserted into the P AmpR The promoter was downstream to obtain the plasmid pCYap-PD-ARx, such as Figure 3As shown. Transform DH5α competent cells and coat LB solid plates (add 50 μg / mL Kan). After a single clone grows the next day, use identification primers Primer9 / Primer10 for bacterial testing, pick positive single clones, inoculate LB medium, culture for 12 hours, extract plasmids, and transform E. coli BL21 (DE3) to obtain potential phage-resistant strains.
[0065] (10) Different positive single clones and control strain E. coli BL21 (DE3) (carrying pCYap plasmid) were selected and inoculated into 3 mL LB liquid medium. After culturing at 37°C and 200 rpm for 6-8 h, 1% inoculum was transferred to LB medium (50 mL / 250 mL conical flask, containing 50 μg / mL kan) and cultured at 37°C and 200 rpm for 8-12 h. Approximately 1×10 9 Add 5 mL of semi-solid LB medium containing 50 μg / mL kan to each cell, mix well, and spread on the upper layer of the LB solid plate (containing 50 μg / mL kan). Leave at room temperature for 5-10 minutes. After solidification, divide the plate into two equal areas and drop 5 μL of a dilution gradient of 10 0 , 10 -2 of phage mixture (the initial phage titer was about 10 8 pfu / mL), mark it, culture it for 12-24h, and observe the plaque formation. Figure 4 shown.
[0066] (11) Select the strain with the best ability to resist infection by phage groups, and preferably use the PD-AR2 sequence as the anti-phage element, whose deoxyribonucleotide sequence is shown in SEQ ID NO.1.
[0067] (12) Using the PD-AR fragment as a template, primers Primer5-2 / Primer6-2 were used to amplify the PD-AR2 fragment and ligated to the fragment carrying P obtained in step (8). EM7 The linearized vector of the promoter was transformed into Escherichia coli BL21 (DE3) after constructing the plasmid according to the method in steps (9) and (10), and the anti-phage performance was tested. Figure 4 As shown, the preferred promoter P EM7 By initiating the transcription and translation of the anti-phage element PD-AR2, the anti-phage phenotype is more significant. Its deoxyribonucleotide sequence is shown in SEQ ID NO.3.
[0068] Embodiment 2
[0069] A genetically engineered strain PR1 carrying the anti-phage action element PD-AR2 and capable of resisting phage group infection was constructed.
[0070] 1. Design and construct the integrated expression tool plasmid and DNA fragment carrying the anti-phage element PD-AR2. The specific steps are as follows:
[0071] (1) PCR amplification or splicing to obtain the anti-phage element expression cassette P of Example 1 EM7 -PD-AR2, targeting the homology arms HA1 and HA2 at both ends of the IS sequence, the homology arm deoxyribonucleotide sequences are shown in SEQ ID NO.4 and SEQ ID NO.5 respectively. Tandem splicing to obtain the anti-phage element integration expression cassette HA1-P EM7 -PD-AR2-HA2, e.g. Figure 5 The primers used for amplification are shown in Table 1.
[0072] (2) According to the gRNA and PAM design requirements, a 20 bp base sequence upstream of the appropriate NGG trinucleotide on the IS sequence of E. coli BL21 (DE3) was selected as the target sequence, i.e., the spacer sequence in the CRISPR / Cas9 system. Its deoxyribonucleotide sequence is shown in SEQ ID NO.6, which can be transcribed into crRNA in E. coli, form a guide RNA (gRNA) with tracrRNA, and then form a complex with the Cas9 protein to guide the Cas9 protein to cut the IS target sequence.
[0073] (3) Amplify or splice the araBAD promoter and regulatory elements, homologous recombination-related enzymes, and P Tet The promoter, spacer, TetR gene, Kan gene, temperature-sensitive replicon element rep101 (Ts) and codon-optimized Cas9 sequence are tandemly spliced to obtain the gene insertion tool CRISPR / Cas9 plasmid pCas9-V2 targeting the IS sequence, such as Figure 6 shown.
[0074] 2. Construction of genetically engineered strains carrying the anti-phage element PD-AR2.
[0075] (1) Pick a single clone of E. coli BL21 (DE3) and inoculate it into LB liquid medium. Cultivate it at 30°C and 200 rpm for 16 h. The next day, transfer 1‰ of the inoculum to fresh LB medium (50 mL / 250 mL conical flask) and grow it to OD 600 =0.4-0.8, prepare the competent state for transformation.
[0076] (2) The plasmid pCas9-V2 was transformed into the competent E. coli BL21 (DE3), coated with LB solid plates supplemented with 50 μg / mL kan, and cultured at 30°C for 16 h; a single clone was picked and inoculated with LB liquid medium supplemented with 50 μg / mL kan, and cultured at 30°C, 200 rpm for 16 h; 1‰ of the inoculum was inoculated with fresh LB medium (supplemented with 50 μg / mL Kan), and the culture was allowed to grow to OD 600 =0.2-0.3, add 50 mg / L arabinose and continue to culture until OD 600 =0.4, prepare the electrocompetent state.
[0077] (3) Take 600 ng of fragment HA1-P EM7 -PD-AR2-HA2, add the electroporation competent cell and mix gently, use a 2mm electroporation cup, set 2.5KV, 6ms electroporation program for electroporation, quickly add 1mL pre-cooled LB medium (containing 10μg / mL tetracycline) on ice and mix gently, transfer to a shaker, 100rpm, 30℃ constant temperature culture for 1-2h, centrifuge to remove the supernatant, keep 100μL of the mixture and spread on LB solid plate (containing 50μg / mL Kan, 10μg / mL tetracycline), and place it at 30℃ constant temperature for 16h.
[0078] (4) After a single clone is grown, use the labeled primers Marker-F / Marker-R to perform PCR to identify the insertion and screen the positive clones. The primers are shown in Table 1.
[0079] (5) Pick different positive monoclones, inoculate them into LB liquid culture medium, culture them at 42°C, 200 rpm overnight, streak them onto antibiotic-free LB solid plates, pick different monoclones and coat them onto LB solid plates (add 50 μg / mL Kan), identify the loss of plasmids, and screen different positive clones with plasmid elimination.
[0080] 3. Plaque detection, the specific steps are as follows:
[0081] (1) After overnight culture of different positive single clones and the starting strain E. coli BL21 (DE3), approximately 1×10 9 Add 5 mL of semi-solid LB medium to each cell and mix well, then spread it on the upper layer of the LB solid plate. Leave it at room temperature for 5-10 minutes. After solidification, divide the plate into two equal areas and drop 5 μL of a 10% dilution gradient into each area. 0 , 10 -2 of phage mixture (the initial phage titer was about 10 8 pfu / mL), mark it, and culture it for 12-24h.
[0082] (2) The corresponding strains with improved resistance to phage colony infection were selected as candidate strains of genetically engineered strain PR1 and named PR1-X (X represents the candidate strain number). PR1-3, PR1-6, PR1-9, and PR1-13 clones were selected as potential multi-phage-resistant strains. Some anti-phage test results are shown in Figure 7 .
[0083] Embodiment 3
[0084] A multi-phage-resistant strain E.coli PRE12 that effectively resists phage group infection was obtained.
[0085] 1. Mutagenesis, isolation and screening to obtain mutant strain PR2 with the ability to resist phage colony infection. The specific steps are as follows:
[0086] (1) Pick E. coli BL21 (DE3) or PR1-X single clone from the LB solid plate, inoculate LB liquid medium (50 mL / 250 mL conical flask), and culture at 37°C, 200 rpm for 12 h.
[0087] (2) Take 5 mL of the above bacterial solution, centrifuge and remove the supernatant, resuspend in PBS three times, collect the bacteria, and resuspend in PBS buffer until the cell count is 10 6 ~10 8 Weigh NTG and mix with bacterial suspension to a final concentration of 0, 0.1, 0.2, 0.3, 0.4, 0.5 and 0.6 g / L of NTG. Immediately place the sample at 30°C and 200 rpm for 20, 40 and 60 min, centrifuge and remove the supernatant, immediately wash with 4°C precooled PBS for 3 times to terminate the reaction, centrifuge and remove the supernatant, add 1 mL of fresh LB medium, resuscitate at 37°C and 200 rpm for 2-3 hours, centrifuge and remove the supernatant, add an equal volume of 0.9% sterile saline to resuspend, and pour into a culture dish.
[0088] (3) Turn on the UV lamp (30W) in advance and irradiate for 20-40 minutes. Place the culture dish with bacterial solution 30 cm under the UV lamp. After irradiating for 60 seconds with the lid on, open the dish lid and irradiate for 10-300 seconds. After irradiation, cover the dish lid and turn off the UV lamp. Take 4 mL of liquid LB in the culture dish, shake to mix, and culture at 37°C in the dark for 12-16 hours.
[0089] (4) Take 1 mL of cultured bacterial solution, add 5 mL of fresh LB medium, and resuscitate at 37°C, 200 rpm for 4-6 h. Take 500 μL of bacterial solution and 50 μL of phage solution with different dilution gradients (the initial phage titer is about 10 8 pfu / mL) and inoculate 50 mL of LB medium until OD 600When the pH reaches about 0.4, take appropriate bacterial solution and spread it on LB solid plate, incubate it at 37℃ for 18-36h, and after colonies grow, streak culture to obtain potential positive multi-resistant phage strain monoclonal clone.
[0090] (5) Select a positive monoclonal clone with good growth and repeat the mutagenesis screening steps (2), (3), and (4) until a positive monoclonal clone with good anti-phage performance and good growth is obtained, which is used as a candidate strain of the genetically engineered strain PR2 and named PR2-X (X represents the candidate strain number). PR2-1, PR2-3, PR2-5, PR2-8, PR2-10, and PR2-12 clones are preferably used as potential multi-phage-resistant strains. Some anti-phage test results are shown in Figure 7 .
[0091] 2. Plaque detection, the specific steps are as follows:
[0092] (1) Positive monoclonal PR2-X, PR1-X and E. coli BL21 (DE3) of different shapes and sizes were selected and inoculated into 3 mL of LB medium respectively. The culture was carried out at 200 rpm and 37°C overnight. Approximately 1×10 9 Add 5 mL of semi-solid LB medium to each cell and mix well, then spread it on the upper layer of the LB solid plate. Leave it at room temperature for 5-10 minutes. After solidification, divide the plate into two equal areas and drop 5 μL of different dilution gradients (10 0 , 10 -2 ) of phage mixture (the initial phage titer was about 10 8 pfu / mL), mark well, and observe the plaque formation after 12-24h of culture. Some anti-phage performance test results are shown in Figure 7 .
[0093] (2) The strain with the best ability to resist phage colony infection was screened from numerous strains of the PR1-X and PR2-X series. The PR1-9 of the PR1-X series was selected for induction screening to obtain the strains PR2-5 and PR2-8 with the best ability to resist phage colony infection. The PR2-8 clone with the best growth status was selected as the optimal strain. The optimal strain was named the multi-phage resistant strain E. coli PRE12, which can effectively adapt to the complex phage contaminated environment where multiple phages break out together.
[0094] (3) The above-mentioned optimal multi-phage-resistant strain E. coli PRE12 is classified and named Escherichia coli. The strain has been deposited in the China Center for Type Culture Collection (CCTCC) on May 4, 2023, with the address: Wuhan University, Wuhan, China, and the deposit number is CCTCCNO: M 2023669.
[0095] Embodiment 4
[0096] Analysis of the anti-phage colony infection and growth abilities of the multi-phage-resistant strain E. coli PRE12.
[0097] 1. Analysis of the antiphage properties of the multi-phage-resistant strain E. coli PRE12.
[0098] (1) In order to detect the practical application value of the multi-phage-resistant strain Escherichia coli E. coli PRE12 in a phage-contaminated environment, the anti-phage performance test was carried out. The specific steps are as follows: Pick E. coli PRE12 and E. coli BL21 (DE3) single clones, inoculate LB liquid culture medium (50mL / 250mL conical flask), culture at 37°C, 200rpm for 12h, and take about 1×10 9 Add 5 mL of semi-solid LB medium to each cell and mix well, then spread it on the top layer of the LB solid plate. Leave it at room temperature for 5-10 minutes. After solidification, divide the plate into 3 equal areas and drop 5 μL of a 10% dilution gradient into each area. 0 , 10 -2 , 10 -4 Phage samples (6 groups of phage samples, numbered P01-P06, originated from the production workshop and laboratory of contaminated phages. After NGS sequencing, each batch of phage contamination was found to be numerous and different, including I: dsDNA phages; II: ssDNA phages, with an initial phage titer of about 10 8 pfu / mL), mark it, culture it at 37℃ for 12-24h, and observe the appearance of plaques.
[0099] (2) The results are as follows Figure 8 As shown in the figure, compared with the plaque formation on E. coli PRE12 plates, different groups of phage samples were more likely to form plaques on E. coli BL21 (DE3) plates, indicating that the E. coli PRE12 strain had a 10% increased ability to resist phage colony infection in the face of a broad spectrum of complex phage environments. 2 -10 6 times, which is significantly better than E. coli BL21 (DE3) and has potential practical application value in phage-contaminated environments.
[0100] 2. Anti-phage performance testing of multi-phage-resistant strains E. coli PRE12, E. coli BL21 (DE3) and ER2566 (Weidi Biotechnology, catalog number: EC1060).
[0101] (1) There are few phage-resistant E. coli expression hosts available on the market. ER2566 has T1 phage resistance and is used to express recombinant proteins. In order to analyze the anti-phage performance of these three expression hosts, plaque detection was performed. The method was the same as before. The phage samples used were phage samples that broke out during the production process, numbered P07 and P08. NGS sequencing identified that the phage types of the two groups of samples were numerous and different. The phage types included I: dsDNA phage; II: ssDNA phage, and the initial phage titer was about 10 8 pfu / mL.
[0102] (2) The results are as follows Fig. 9 As shown, the multi-phage-resistant strain E. coli PRE12 has significantly better anti-phage performance and application potential than E. coli BL21 (DE3) and ER2566.
[0103] 3. Determination of the growth curve of the multi-resistant phage strain E.coli PRE12.
[0104] (1) Determine the growth curves of E.coli BL21 (DE3) and E.coli PRE12. The specific steps are as follows: E.coliBL21 (DE3) and E.coli PRE12 were inoculated into 3 mL of fresh LB medium, respectively, and cultured at 37°C, 200 rpm for 12 h. The next day, 500 μL of each was taken into 50 mL of LB medium (250 mL conical flask) and cultured at 37°C, 200 rpm for 12 h. Samples of 1 mL were taken at 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, and 8h, and OD was determined using a UV spectrophotometer. 600 .
[0105] (2) The results are as follows Fig.10 As shown, there was no significant difference in the cell growth ability between E. coli BL21(DE3) (circles) and E. coli PRE12 (squares).
[0106] 4. Determination of protein expression level of multi-resistant phage strain E. coli PRE12, the specific steps are as follows:
[0107] (1) Preparation of recombinant protein expression plasmid
[0108] To obtain the EGFP protein expression plasmid, primers P01-F / P01-R were used to amplify the DNA sequence shown in SEQ ID NO.7 and primers P-VF / P-VR were used to amplify pET-28a(+) to obtain a linearized vector. The EGFP fragment was inserted into pET-28a(+) using the above-mentioned one-step cloning kit to obtain the pET-28a-EGFP recombinant protein expression plasmid. The primers are shown in Table 1.
[0109] (2) Construction of recombinant protein expression strain
[0110] The EGFP protein expression plasmid pET-28a-EGFP (target protein carries a His tag, 29.2 kDa) was transformed into E. coli BL21 (DE3), E. coli PRE12 and ER2566, respectively, to obtain protein expression strains of different hosts for EGFP.
[0111] (3) Recombinant strains induce protein expression
[0112] Pick out E. coli BL21 (DE3), E. coli PRE12 and ER2566 recombinant strains carrying EGFP expression plasmids and inoculate 3 mL of liquid LB medium (50 μg / mL kan) respectively, and culture at 37°C, 200 rpm for 12 h. Take 500 μL of the first-level seed solution, transfer to 50 mL of liquid LB medium (250 mL conical flask), and culture at 37°C, 200 rpm for 10-14 h. The next day, take 5 mL of the second-level seed solution, transfer to 500 mL of TB medium (3L conical flask), and culture at 37°C, 200 rpm until OD 600 =1.2, cool to 25℃, and use IPTG with a final concentration of 0.5mM to induce expression for 12h. Collect the bacteria by centrifugation, weigh 1g of wet bacteria, use PBS buffer, break the bacteria at 1:20 (1g of wet bacteria corresponds to 20mL PBS), collect the supernatant by centrifugation, resuspend the precipitate with 20mL PBS, prepare 40μL supernatant + 10μL 5× loading buffer and 40μL resuspended precipitate + 10μL 5× loading buffer, respectively, boil for 5min, and perform SDS-PAGE electrophoresis detection. The results are as follows Fig.11 As shown, the recombinant protein expression performance of E. coli PRE12 is generally equivalent to or better than that of E. coli BL21 (DE3) and ER2566.
[0113] SEQ ID NO.1
[0114]
[0115] SEQ ID NO.2
[0116]
[0117] SEQ ID NO.3
[0118] 5’-TGTTGATACAACCATAAAATGATAATTACACCCATAAATTGATAATTATCACACCCACGGGGATCCGCGGCCGCGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAAGGTGAGGAACTAAACC-3’
[0119] SEQ ID NO.4
[0120] 5’-GGTGATGCTGCCAACTTACTGATTTAGTGTATGATGGTGTTTTTGAGGTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCCTGTTCAGCTACTGACGGGGTGGTGCGTAACGGCAAAAGCACCGCCGGACATCAGCGCTATCTCTGCTCTCACTGCCGTAAAACATGGCAACTGCAGTTCACTTACACCGCTTCTCAACCCGGTACGCACCAGAAAATCATTGATATGGCCATGAATGGCGTTGGATGCCGGGCAACTGCCCGCATTATGGGCGTTGGCCTCAACACGATTTTACGTCACTTAAAAAACTCAGGCCGCAGTCGGTAACCTCGCGCATACAGCCGGGCAGTG-3’
[0121] SEQ ID NO.5
[0122] 5’-GTGGGGCTATGTCGGGGCTAAATCGCGCCAGCGCTGGCTGTTTTACGCGTATGACAGGCTCCGGAAGACGGTTGTTGCGCACGTATTCGGTGAACGCACTATGGCGACGCTGGGGCGTCTTATGAGCCTGCTGTCACCCTTTGACGTGGTGATATGGATGACGGATGGCTGGCCGCTGTATGAATCCCGCCTGAAGGGAAAGCTGCACGTAATCAGCAAGCGATATACGCAGCGAATTGAGCGGCATAACCTGAATCTGAGGCAGCACCTGGCACGGCTGGGACGGAAGTCGCTGTCGTTCTCAAAATCGGTGGAGCTGCATGACAAAGTCATCGGGCATTATCTGAACATAAAACACTATCAATAAGTTGGAGTCATTACC-3’
[0123] SEQ ID NO.6
[0124] 5’-CGTCATCGTCTGCGCGGAAA-3’
[0125] SEQ ID NO.7
[0126] 5’-ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA-3’
Claims
1. Escherichia coli PRE12, deposited on May 4, 2023 in China Center for Type Culture Collection, Wuhan University, China, with the deposit number CCTCC NO: M 2023669.
2. Use of the Escherichia coli PRE12 or its bacterial solution as described in claim 1 in resisting phage infection and / or preventing and treating phage infection.
3. The use according to claim 2, characterized in that: The phage is selected from one or more of dsDNA phage and ssDNA phage.
4. Use of the Escherichia coli PRE12 or its bacterial solution as described in claim 1 in expressing recombinant proteins.
5. An isolated anti-phage element PD-AR2, characterized in that It consists of a nucleic acid with a nucleotide sequence as shown in SEQ ID NO.
1.
6. Use of the anti-phage element PD-AR2 according to claim 5 in improving the resistance of Escherichia coli to phage infection.
7. The use according to claim 6, characterized in that: The bacteriophage is selected from one or more of dsDNA phage and ssDNA phage.
8. An expression vector into which the isolated anti-phage element PD-AR2 according to claim 5 is inserted as a nucleic acid fragment.
Citation Information
Patent Citations
Broad-spectrum antiphage escherichia coli BL21(DE3)-PR and application thereof
CN109370936A
Broad-spectrum anti-phage E. Coli BL21-(DE3)-PR and application thereof
CN109762770A
Screening method of phage resistance engineering strain
CN115838667A
Transformation method of bacterial anti-bacteriophage and engineering strain
CN115927421A
